Last reviewed · How we verify

bupivacaine/ neostigmine.

Ain Shams University · FDA-approved active Small molecule

bupivacaine/ neostigmine. is a Local anesthetic combination Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Local and regional anesthesia (epidural, spinal, peripheral nerve blocks), Prolongation of local anesthetic duration in surgical procedures.

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while neostigmine enhances and prolongs this effect by inhibiting acetylcholinesterase.

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while neostigmine enhances and prolongs this effect by inhibiting acetylcholinesterase. Used for Local and regional anesthesia (epidural, spinal, peripheral nerve blocks), Prolongation of local anesthetic duration in surgical procedures.

At a glance

Generic namebupivacaine/ neostigmine.
SponsorAin Shams University
Drug classLocal anesthetic combination
TargetVoltage-gated sodium channels (bupivacaine); acetylcholinesterase (neostigmine)
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that reversibly blocks voltage-gated sodium channels in nerve cell membranes, preventing depolarization and transmission of pain signals. Neostigmine, an acetylcholinesterase inhibitor, potentiates cholinergic activity and may enhance the duration and quality of the local anesthetic block through modulation of neuromuscular and autonomic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bupivacaine/ neostigmine.

What is bupivacaine/ neostigmine.?

bupivacaine/ neostigmine. is a Local anesthetic combination drug developed by Ain Shams University, indicated for Local and regional anesthesia (epidural, spinal, peripheral nerve blocks), Prolongation of local anesthetic duration in surgical procedures.

How does bupivacaine/ neostigmine. work?

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while neostigmine enhances and prolongs this effect by inhibiting acetylcholinesterase.

What is bupivacaine/ neostigmine. used for?

bupivacaine/ neostigmine. is indicated for Local and regional anesthesia (epidural, spinal, peripheral nerve blocks), Prolongation of local anesthetic duration in surgical procedures.

Who makes bupivacaine/ neostigmine.?

bupivacaine/ neostigmine. is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

What drug class is bupivacaine/ neostigmine. in?

bupivacaine/ neostigmine. belongs to the Local anesthetic combination class. See all Local anesthetic combination drugs at /class/local-anesthetic-combination.

What development phase is bupivacaine/ neostigmine. in?

bupivacaine/ neostigmine. is FDA-approved (marketed).

What are the side effects of bupivacaine/ neostigmine.?

Common side effects of bupivacaine/ neostigmine. include Hypotension, Bradycardia, Nausea and vomiting, Neurological toxicity (at high doses), Allergic reactions.

What does bupivacaine/ neostigmine. target?

bupivacaine/ neostigmine. targets Voltage-gated sodium channels (bupivacaine); acetylcholinesterase (neostigmine) and is a Local anesthetic combination.

Related